StockNews.com Initiates Coverage on Aspira Women’s Health (NASDAQ:AWH)

Equities researchers at StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued on Monday. The brokerage set a “hold” rating on the stock.

Aspira Women’s Health Trading Up 0.3 %

Aspira Women’s Health stock opened at $0.72 on Monday. Aspira Women’s Health has a 52 week low of $0.67 and a 52 week high of $5.65. The stock has a market cap of $12.00 million, a price-to-earnings ratio of -0.60 and a beta of 1.39. The company’s 50-day moving average price is $0.79 and its two-hundred day moving average price is $0.98.

Institutional Trading of Aspira Women’s Health

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co bought a new position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned approximately 0.19% of Aspira Women’s Health as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.